Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

WAT

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

WAT

AI Research Report

Powered by Claude

Ready to analyze WAT

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Waters Corp

Waters Corp

Life Sciences Tools & Services·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1995-11-17
📅 Earnings in 27d (May 12)
  • Yahoo·12h ago

    Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules

    Waters Corporation (NYSE: WAT) today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput.

  • Benzinga·1d ago

    UBS Maintains Neutral on Waters, Lowers Price Target to $330

    UBS analyst Lu Li maintains Waters (NYSE:WAT) with a Neutral and lowers the price target from $370 to $330.

  • Yahoo·2d ago

    Waters (WAT) Is Up 5.2% After FDA Clears At-Home HPV Test Kit - What's Changed

    Waters Corporation recently reported that the FDA cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay for at-home use, enabling prescription-based, mail-in cervical cancer screening with coverage from private insurance, Medicaid, and Medicare. This clearance underscores Waters’ push deeper into diagnostics following its merger with BD’s Biosciences & Diagnostic Solutions business, positioning the company at the forefront of expanding access to cervical...

  • Yahoo·6d ago

    Sector Update: Health Care Stocks Advance in Afternoon Trading

    Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index and the State Street He

  • Benzinga·6d ago

    Waters Stock Shoots Higher As FDA Clears At-Home Cervical Cancer Screening Kit

    Waters shares rise after FDA clears at-home HPV test kit, boosting screening access; technicals show resistance near key levels.

  • Yahoo·6d ago

    Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay

    Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening.

  • Benzinga·6d ago

    Waters Corp's Onclarity HPV Self-Collection Kit Cleared By FDA For At-Home Use To Expand Cervical Cancer Screening

    FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows.At-home self-collection reduces significant

  • SeekingAlpha·6d ago

    ClearBridge Dividend Strategy Q1 2026 Portfolio Positioning

    We bought four “new” holdings in the quarter. Two of the four — Blackstone and Otis — we have owned before.

  • View all news →

Analyst Consensus

Buy
Based on 28 analysts
Period: 2026-04-01
16 Buy (57%)12 Hold (43%)0 Sell (0%)
Rating Distribution
Strong Buy
8
Buy
8
Hold
12
Sell
0
Strong Sell
0
Trend
2026-04
16/12/0
2026-03
16/12/0
2026-02
14/11/0
2026-01
11/11/0
⚠️
Dilution risk detected

5 offering-related filings in the last 60 filings. Latest: 424B2 on 2026-03-19. View all →

Recent insider activity

View all →
  • 4PRIMARY DOCUMENT
    8d ago
  • 4PRIMARY DOCUMENT
    13d ago
  • 4PRIMARY DOCUMENT
    13d ago
  • 4PRIMARY DOCUMENT
    28d ago
  • 4PRIMARY DOCUMENT
    Mar 10
NEW YORK STOCK EXCHANGE, INC.Market closed
Waters Corp
Life Sciences Tools & Services
$330.98
$6.30 (+1.94%)
Open
$325.84
Prev close
$324.68
Day range
$323.47 – $333.47
52W range
$275.05 – $414.15
Mkt cap
$32.47B
P/E
50.7
EPS
$10.76
Beta
1.22

Fundamentals

Valuation
Market Cap
$32.47B
P/E (TTM)
50.66S&P avg ~22
P/S (TTM)
10.29S&P avg ~2.8
P/B
8.83S&P avg ~4.5
P/FCF
60.31S&P avg ~26
EPS (TTM)
$10.76
Book/sh
$43.01
Cash/sh
$9.87
Profitability
Gross Margin
59.28%avg ~45%
Operating Margin
25.36%avg ~15%
Net Margin
20.30%avg ~12%
ROE
28.52%avg ~18%
ROA
13.35%avg ~7%
ROI
17.44%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
6.99%
Rev Growth 5Y
6.00%
EPS Growth YoY
0.51%
EPS Growth 5Y
5.19%
Current Ratio
—
Quick Ratio
1.27
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.22
52W High
$414.15
52W Low
$275.05
Avg Vol (10D)
876.0K
Avg Vol (3M)
947.1K
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (28)
Price Performance
5D+5.63%
MTD+9.03%
3M-18.14%
6M-0.90%
YTD-14.52%
1Y+3.18%

Factor Grades

View details →
C+
Overall score: 54/100
D-
Valuation
C+
Growth
B+
Profitability
D-
Momentum
A-
Financial Health